Experimental Immunotherapy Could Help High-Risk Bladder Cancer Patients Skip Cystectomy
A Mayo Clinic–led international phase 3 trial reports that a new intravesical oncolytic immunotherapy, cretostimogene grenadenorepvec, may help many people with high-risk, BCG-unresponsive non-muscle-invasive bladder...















